These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8638215)

  • 21. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.
    Muramatsu S; Fujimoto K; Ikeguchi K; Shizuma N; Kawasaki K; Ono F; Shen Y; Wang L; Mizukami H; Kume A; Matsumura M; Nagatsu I; Urano F; Ichinose H; Nagatsu T; Terao K; Nakano I; Ozawa K
    Hum Gene Ther; 2002 Feb; 13(3):345-54. PubMed ID: 11860702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats.
    Ryu MY; Lee MA; Ahn YH; Kim KS; Yoon SH; Snyder EY; Cho KG; Kim SU
    Cell Transplant; 2005; 14(4):193-202. PubMed ID: 15929554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatments for Parkinson's Disease -Essential Knowledge for General Physicians - Topics: VIII. Future Treatment of Parkinson's Disease].
    Baba K; Mochizuki H
    Nihon Naika Gakkai Zasshi; 2015 Aug; 104(8):1591-6. PubMed ID: 30160458
    [No Abstract]   [Full Text] [Related]  

  • 24. [Gene therapy of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase genes in rat model of Parkinson's disease].
    Lu LL; Su Y; Duan CL; Zhao CL; Su YJ; Wu J; Zhao HY; Xu QY; Yang H
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1528-32. PubMed ID: 15500713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models.
    Kang UJ; Lee WY; Chang JW
    Hum Cell; 2001 Mar; 14(1):39-48. PubMed ID: 11436352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Movement disorders: towards new therapies in Parkinson's disease.
    Antonini A
    Lancet Neurol; 2012 Jan; 11(1):7-8. PubMed ID: 22172611
    [No Abstract]   [Full Text] [Related]  

  • 27. Biomedicine. Combating Parkinson's disease--step three.
    Olson L
    Science; 2000 Oct; 290(5492):721-4. PubMed ID: 11184202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
    Wachtel SR; Bencsics C; Kang UJ
    J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for Parkinson's disease.
    Lawlor PA; During MJ
    Expert Rev Mol Med; 2004 Mar; 6(5):1-18. PubMed ID: 15000692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Parkinson's disease--the molecular mechanism].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1341-52. PubMed ID: 1972586
    [No Abstract]   [Full Text] [Related]  

  • 31. [Gene therapy in Parkinson disease: a promising future treatment?].
    Golé C; Reboul R; Pisano P
    Therapie; 2011; 66(5):413-9. PubMed ID: 22031685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
    Zhang Y; Calon F; Zhu C; Boado RJ; Pardridge WM
    Hum Gene Ther; 2003 Jan; 14(1):1-12. PubMed ID: 12573054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gene therapy for Parkinson's disease].
    Fraix V
    Rev Med Interne; 2004 Jul; 25(7):524-7. PubMed ID: 15219371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.
    Douglas MR
    Expert Rev Neurother; 2013 Jun; 13(6):695-705. PubMed ID: 23739006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain.
    Cederfjäll E; Sahin G; Kirik D
    Neurobiol Dis; 2012 Nov; 48(2):222-7. PubMed ID: 22048069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospects on gene therapy of Parkinson disease].
    Ozawa K
    Nihon Naika Gakkai Zasshi; 1998 Jun; 87(6):1149-54. PubMed ID: 9702031
    [No Abstract]   [Full Text] [Related]  

  • 37. Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson's disease.
    Kunugi H; Kawada Y; Hattori M; Ueki A; Otsuka M; Nanko S
    Am J Med Genet; 1998 Mar; 81(2):131-3. PubMed ID: 9613851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease.
    Moffat M; Harmon S; Haycock J; O'Malley KL
    Exp Neurol; 1997 Mar; 144(1):69-73. PubMed ID: 9126154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.
    Lundberg C; Horellou P; Mallet J; Björklund A
    Exp Neurol; 1996 May; 139(1):39-53. PubMed ID: 8635567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex.
    Cao L; Zheng ZC; Zhao YC; Jiang ZH; Liu ZG; Chen SD; Zhou CF; Liu XY
    Hum Gene Ther; 1995 Nov; 6(11):1497-501. PubMed ID: 8573622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.